Table 6 |
|||
|
Independent correlates of total cholesterol in women only, determined by using multivariate linear regression (GEE) |
|||
|
Variablea |
Parameter estimate |
95% CI |
P value |
|
|
|||
|
Age (years) |
0.009 |
0.006, 0.011 |
< 0.0001 |
|
SLEDAI-2K scoreb |
0.04 |
0.036, 0.046 |
< 0.0001 |
|
Disease duration (years) |
-0.004 |
-0.006, -0.0017 |
0.0008 |
|
Corticosteroids |
0.31 |
0.26, 0.36 |
< 0.0001 |
|
Antimalarialsc |
-0.41 |
-0.45, -0.36 |
< 0.0001 |
|
Immunosuppressivesd |
0.15 |
0.11, 0.20 |
< 0.0001 |
|
Antihypertensivese |
0.19 |
0.14, 0.24 |
< 0.0001 |
|
Hypertensionf |
0.25 |
0.19, 0.32 |
< 0.0001 |
|
Lipid-lowering meds (statins) |
-0.09 |
-0.15, -0.03 |
0.004 |
|
HRTg |
0.17 |
0.09, 0.25 |
< 0.0001 |
|
|
|||
|
GEE, generalized estimating equation; CI, confidence interval. aAll variables measured coincident with measurement of total cholesterol. bSLE Disease Activity Index 2000; scores range from 0 to 105, with higher scores indicating more-active disease. cAntimalarials include chloroquine and hydroxychloroquine. d Immunosuppressives include methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, and cyclophosphamide. eAntihypertensives include all classes of drugs used to lower blood pressure. fHypertension is defined as systolic BP ≥ 140 mm Hg or diastolic BP ≥ 90 mm Hg. gEstrogen with/without progestin hormone-replacement therapy. |
|||
|
Nikpour et al. Arthritis Research & Therapy 2010 12:R125 doi:10.1186/ar3063 |
|||